tbuckley/cabot-search huggingface dataset:
The importance of altruism to biomarker development for pancreatic cancer.
Authors: Danny HJ Heo, Corinne DeCicco, Tori Singer, Vijetha Vemulapalli, Christopher Yee, Michael A. Kiebish, Eric M. Grund, Viatcheslav R Akmaev, Niven R. Narain, Kevin F. Kennedy, A. James Moser
Journal: Journal of Clinical Oncology (2019)

11626 Background: Longitudinal donation of tissue and health information by patients with pancreatic ductal adenocarcinoma (PDAC) is critical to validating algorithms for precision treatment. Unlike therapeutic trials offering potential survival benefit, factors motivating long-term participation in biomarker studies are poorly understood. We hypothesized that long-term participation (PART) depends on identifiable factors motivating study volunteers in non-therapeutic biomarker studies. Methods: A prospective, single-institution biomarker study was screened to identify participants with, or at elevated risk for, PDAC and periampullary cancer (Jul 2015-Dec 2018). Study consent precluded individual receipt of value or research benefit. Detailed biospecimen and clinical data (n = 294) were analyzed using multivariable modeling and Bayesian AI (bAIcis) to characterize motivators of PART. Results: Of 294 participants, 185 had PDAC (63%); 89 had premalignant lesions (30%) or tumors (20; 7%) mimicking PDAC. Mean age was 68 years, 54% male, 26% with prior cancers, and 18% family PDAC history. Treatment was not indicated (37% no cancer), potentially curative (27%), non-curative (35%); or refused (1.4%). Bayesian AI showed PDAC diagnosis to be the leading predictor of PART. Using multivariable modeling and adjusting for the competing risk of death, none of the following domains predicted PART: demographics, perceived personal/family cancer risk, health insurance type, median income, housing price, travel time/distance or charitable expense, or primary institution providing clinical treatment. The following motivators were significant predictors of PART: worsening symptoms (McGill Brisbane &gt; 9; HR 0.54; p = 0.045), non-curative treatment (HR 0.55; p = 0.042); and shorter AJCC predicted survival (HR 0.77, p = 0.042). Conclusions: Volunteers with symptomatic PDAC and shorter predicted survival who received non-curative treatment were more motivated to participate in biomarker discovery. Volunteers were undeterred by apparent self-interests such as travel time, insurance type, income, charitable expense, and personal life expectancy. We attribute these findings to altruistic behaviors among patients most likely to die of PDAC.
Legacy Data Confound Genomics Studies
Authors: Luke Anderson-Trocmé, Rick Farouni, Mathieu Bourgey, Yoichiro Kamatani, Koichiro Higasa, Jeong-Sun Seo, Changhoon Kim, Fumihiko Matsuda, Simon Gravel
Journal: Molecular Biology and Evolution (2019)

Abstract Recent reports have identified differences in the mutational spectra across human populations. Although some of these reports have been replicated in other cohorts, most have been reported only in the 1000 Genomes Project (1kGP) data. While investigating an intriguing putative population stratification within the Japanese population, we identified a previously unreported batch effect leading to spurious mutation calls in the 1kGP data and to the apparent population stratification. Because the 1kGP data are used extensively, we find that the batch effects also lead to incorrect imputation by leading imputation servers and a small number of suspicious GWAS associations. Lower quality data from the early phases of the 1kGP thus continue to contaminate modern studies in hidden ways. It may be time to retire or upgrade such legacy sequencing data.
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial
Authors: Daniel J F M Thuijs, A Pieter Kappetein, Patrick W Serruys, Friedrich-Wilhelm Mohr, Marie-Claude Morice, Michael J Mack, David R Holmes, Nick Curzen, Piroze Davierwala, Thilo Noack, Milan Milojevic, Keith D Dawkins, Bruno R da Costa, Peter Jüni, Stuart J Head, Filip Casselman, Bernard de Bruyne, Evald Høj Christiansen, Juan M. Ruiz-Nodar, Paul Vermeersch, Werner Schultz, Manel Sabaté, Giulio Guagliumi, Herko Grubitzsch, Karl Stangl, Olivier Darremont, M. Bentala, Peter den Heijer, Istvan Preda, Robert Stoler, Michael J. Mack, Tamás Szerafin, John K. Buckner, Myles S. Guber, Niels Verberkmoes, Ferdi Akca, Ted Feldman, Friedhelm Beyersdorf, Benny Drieghe, Keith Oldroyd, Geoff Berg, Anders Jeppsson, Kimberly Barber, Kevin Wolschleger, John Heiser, Pim van der Harst, Massimo A. Mariani, Hermann Reichenspurner, Christoffer Stark, Mika Laine, Paul C. Ho, John C. Chen, Richard Zelman, Phillip A. Horwitz, Andrzej Bochenek, Agata Krauze, Christina Grothusen, Dariusz Dudek, George Heyrich, Piroze Davierwala, Thilo Noack, Philippe Kolh, Victor LeGrand, Pedro Coelho, Stephan Ensminger, Boris Nasseri, Richard Ingemansson, Goran Olivecrona, Javier Escaned, Reddy Guera, Sergio Berti, Marie-Claude Morice, Alaide Chieffo, Nicholas Burke, Michael Mooney, Alvise Spolaor, Christian Hagl, Michael Näbauer, Maarten Jan Suttorp, Ronald A. Stine, Thomas McGarry, Scott Lucas, Knut Endresen, Andrew Taussig, Kevin Accola, Umberto Canosi, Ivan Horvath, Louis Cannon, John D. Talbott, Chris W. Akins, Robert Kramer, Michael Aschermann, William Killinger, Inga Narbute, David R. Holmes, Francesco Burzotta, Ad Bogers, Felix Zijlstra, Helene Eltchaninoff, Jacques Berland, Giulio Stefanini, Ignacio Cruz Gonzalez, Uta Hoppe, Stefan Kiesz, Bartlomiej Gora, Anders Ahlsson, Matthias Corbascio, Thomas Bilfinger, Didier Carrie, Didier Tchétché, Karl-Eugen Hauptman, Elisabeth Stahle, Stefan James, Sigrid Sandner, Günther Laufer, Irene Lang, Adam Witkowski, Vinod Thourani, Harry Suryapranata, Simon Redwood, Charles Knight, Philip MacCarthy, Nick Curzen, Adam de Belder, Adrian Banning, Anthony Gershlick
Journal: The Lancet (2019)
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
Authors: Christiane Pott, Laurie H. Sehn, David Belada, John Gribben, Eva Hoster, Brad Kahl, Britta Kehden, Emmanuelle Nicolas-Virelizier, Nathalie Spielewoy, Guenter Fingerle-Rowson, Chris Harbron, Kirsten Mundt, Elisabeth Wassner-Fritsch, Bruce D. Cheson
Journal: Leukemia (2019)

We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), end of induction (EOI), and every 6–24 months post-EOI/discontinuation by real-time quantitative PCR. At MI, 41/52 (79%) patients receiving G-Benda were MRD-negative vs. 17/36 (47%) patients receiving Benda alone (p = 0.0029). At EOI, 54/63 (86%) patients receiving G-Benda were MRD-negative vs. 30/55 (55%) receiving Benda alone (p = 0.0002). MRD-negative patients at EOI had improved progression-free survival (HR, 0.33, 95% CI, 0.19–0.56, p < 0.0001) and overall survival (HR, 0.39, 95% CI, 0.19–0.78, p = 0.008) vs. MRD-positive patients, and maintained their MRD-negative status for longer if they received G maintenance than if they did not. These results suggest that the addition of G to Benda-based treatment during induction can significantly contribute to the speed and depth of response, and G maintenance in MRD-negative patients potentially delays lymphoma regrowth.
Simultaneous transrectal ultrasound and photoacoustic human prostate imaging
Authors: Sri-Rajasekhar Kothapalli, Geoffrey A. Sonn, Jung Woo Choe, Amin Nikoozadeh, Anshuman Bhuyan, Kwan Kyu Park, Paul Cristman, Richard Fan, Azadeh Moini, Byung Chul Lee, Jonathan Wu, Thomas E. Carver, Dharati Trivedi, Lillian Shiiba, Idan Steinberg, David M. Huland, Morten F. Rasmussen, Joseph C. Liao, James D. Brooks, Pierre T. Khuri-Yakub, Sanjiv S. Gambhir
Journal: Science Translational Medicine (2019)

Transrectal ultrasound and photoacoustic imaging simultaneously provide structural and molecular contrasts of normal and cancerous human prostates.
Severity, implications, and understanding of cancer related fatigue in cancer survivors of South Asian ethnicity.
Authors: Harleen Kaur Nayyar, Shaik Maheboob Hussain, Ruchika Thakur, Neha Sonthwal, Harit Kumar Chaturvedi, Alok Gupta
Journal: Journal of Clinical Oncology (2019)

e23177 Background: Cancer Related Fatigue (CRF) is a common debilitating symptom among cancer survivors that interferes with their Quality of Life (QOL). We evaluated incidence, severity, perception and implications of CRF on QOL among cancer survivors of South Asian ethnicity. Methods: Between July &amp; December 2018, cancer survivors who visited cancer follow up clinic were asked to participate in this study by filling CRF questionnaire which focused on evaluating an individual’s assessment of severity, perception of causes and implications of CRF on their QOL as well as the measures taken to overcome CRF. Results: 160 cancer survivors, median age 52 years, 125 female &amp; 34 male with most common diagnosis of breast cancer(60%) participated in the study. All survivors had received ≥2 treatment modalities. Overall, 133(84%) underwent surgery, 144(91%) received chemotherapy, 103(65%) received radiation therapy, 60(38%) received hormonal therapy &amp; 34(21%) received targeted therapy. 36(23%) experienced weight loss and 26(16%) required blood transfusion. 148(93%) survivors reported CRF of any grade. 82(52%) reported moderate intensity CRF(affecting work but not activities of daily living) while 33(21%) reported severe intensity CRF (affecting activities of daily living). CRF was perceived as generalized weakness by 137(86.2%), emotional labiality by 42(26%), diminished concentration/attention span by 36(23%) and decreased motivation/interest in usual activities by 29(18%) survivors. CRF was attributed to treatment of cancer by 137(86%), psychological and social factors by 50(31%), cancer itself by 34(21%) and environmental /genetic factors by 16(10%) survivors. CRF adversely affected various aspects of QOL including activities of daily living in 79(50%), mood in 74(47%), professional work in 46(29%) and interpersonal relationships in 36(23%) survivors. To overcome CRF, 70(44%) survivors increased physical activity, 61(38%) resorted to mind-body interventions, 29 (18%) took pharmacological intervention and 25 (16%) resorted to psychosocial interventions. CRF resolved within 3 months after completion of therapy in 29(18%), 3-6 months in 23(15%), 6-12 months in 23(15%) and &gt; 12 months in 1 survivor. CRF persisted in 78(49%) survivors. Conclusions: Incidence &amp; severity of CRF is high in cancer survivors of South Asian ethnicity. Persistence of CRF beyond treatment completion significantly affects QOL and remains a poorly understood &amp; incompletely addressed health issue among cancer survivors. More research is warranted in this field.
Long-Term Outcomes After Early-Onset Myocardial Infarction
Authors: Giuseppe Maglietta, Maddalena Ardissino, Guidantonio Malagoli Tagliazucchi, Caterina Disisto, Piera Angelica Merlini, Antonio Crocamo, Maria Francesca Notarangelo, Paolo Calabrò, Carlo Berzuini, Diego Ardissino
Journal: Journal of the American College of Cardiology (2019)
Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn’s Disease
Authors: Christopher Ma, Krisztina B. Gecse, Marjolijn Duijvestein, William J. Sandborn, Guangyong Zou, Lisa M. Shackelton, Larry W. Stitt, Claire E. Parker, Peter Bossuyt, Mark Löwenberg, Reena Khanna, Severine Vermeire, Paul Rutgeerts, Brian G. Feagan, Vipul Jairath, Geert R. D’Haens
Journal: Clinical Gastroenterology and Hepatology (2019)
Quality of life (QoL) improvements in 1,464 patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X) in Brazil: Updated results from a large pt cohort, including analysis as a function of pts’ ECOG PS
Authors: C. Oliveira, R. Ribeiro, J. G. Segalla, S. Tessaro, S. Cabral, F. A. Franke, U. De Paula, G. L. Moura, M. R. Perdicaris, B. Garicochea
Journal: Journal of Clinical Oncology (2006)

8599 Background: The oral fluoropyrimidine capecitabine is highly active and well tolerated as single-agent therapy and extends survival when added to docetaxel in pretreated MBC. QoL data would enhance understanding of X’s pt benefits. Methods: QoL was evaluated in women with anthracycline ± taxane-pretreated MBC while receiving X (baseline, before cycle 1, at weeks 7 and 13, and at treatment end) using EORTC QLQ C-30 (v3.0) and BR-23 questionnaires. We used linear models with repeated measures (generalized estimating questions technique) and SAS (v8.2) to determine improvement, stabilization or worsening of QoL scores from week 7 onwards. Each questionnaire item was analyzed as a function of pts’ ECOG status before first cycle and the evaluation periods. Results: Baseline characteristics of the 1,464 evaluable pts were: median age 54 years (range 22–92); 42% had ECOG 0. As expected, pts with worse initial PS (ECOG ≥2) had lower mean scores during treatment. Regardless of baseline ECOG score, X therapy was associated with significant (p&lt;0.0001 unless stated) improvements in pts’ perception of: role functioning (p=0.001), pain, nausea/vomiting, fatigue, constipation, emotional functioning, and global health status. Capecitabine was also associated with significant improvements in pts’ perception of systemic therapy side effects (p&lt;0.0001), breast symptoms (p&lt;0.0001), arm symptoms (p=0.0047), hair loss (p&lt;0.0001), and future perspective (p&lt;0.0001). Conclusions: Pts receiving X had substantial improvements in almost all functional and symptomatic QoL domains. These findings highlight the importance of considering QoL and other measurable benefits of oral treatments alongside well-established measures of clinical evaluation in pts with metastatic disease. The QoL benefits, together with other proven clinical outcomes, suggest that early use of X in MBC would be of benefit to pts. No significant financial relationships to disclose.
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis
Authors: Stefan Knop, Monika Engelhardt, Peter Liebisch, Christoph Meisner, Ernst Holler, Bernd Metzner, Dietrich Peest, Martin Kaufmann, Donald Bunjes, Christian Straka, Thomas Fischer, Orhan Sezer, Marcus Hentrich, Helmut Ostermann, Florian Bassermann, Georg Hess, Bernd Hertenstein, Mathias Freund, Martin Kropff, Christian A. Schmidt, Hans-Heinrich Wolf, Wolfram Jung, Norbert Frickhofen, Stephan Mielke, Ralf C. Bargou, Georg Maschmeyer, Mirija Svaldi, Christian H. Langer, Martin Gramatzki, Holger Hebart, Lothar Kanz, Hermann Einsele
Journal: Leukemia (2019)
Long-term follow-up of endogenous erythropoietin, VEGF levels and red blood count in patients receiving different antiangiogenic treatment
Authors: J. Bloch, R. Mouawad, J. Spano, S. Vigniot, N. Magné, D. Khayat
Journal: Journal of Clinical Oncology (2009)

e14648 Background: Anemia, commonly defined as a hemoglobin level of &lt;12 g/dL, occurs in over 30% of cancer patients at any time point and its incidence increases with treatment. The concept of antiangiogenic treatment for solid tumors has recently emerged and we wondered why patients under such kind of treatment did not experience anemia requiring transfusion or the use of erythropoietin. The goal of this study is to follow-up endogenous serum EPO, VEGF concentrations, hemoglobin (Hb) and hematocrit (Ht) levels in various metastatic cancers patients receiving different anti-angiogenic treatment and to try to establish the possible relation between these parameters. Patients and Methods: 30 patients (20 men and 10 women) with different cancer type (20 RCC and 10 thyroids) with a median age of 56 year were included in this study. All of theme received a angiogenic therapy. The values of hemoglobin, hematocrit and platelet were determined in all patients Endogenous serum erythropoietin,VEGF serum concentrations were quantified using Elisa test and at day 0 and each 4 weeks. Statistical analysis of the results was performed using Mann-Whitney U test and the correlation analysis was performed using Pearson test. Results: At day 0, The mean level of endogenous EPO and VEGF serum concentration was significantly higher in patients as compared to healthy donors (p=0.005 and p=0.0001 respectively). Regarding anemia, 65 % of the patients had a mild grade of anemia with 11.5 g/l of hemoglobin (Hb) and 36.4 % of Ht. Patients with normal Hb values had a lower mean EPO serum concentration and high VEGF concentration as compared to patients with anemia. A negative correlation was observed between EPO serum concentration and Hb and Ht levels. In overall patients, the follow-up of these parameters showed an increase in endogenous EPO and VEGF concentrations which was confirmed during the subsequent cycles treatment without any increase in Hb and Ht count.The study of these parameters patient by patient and the relation with the clinical response is ongoing and will be more developed. Conclusions: In overall patients we were not able to find any correlation between Hb or Ht, levels and EPO concentrations but a relation between the production of EPO and VEGF is observed. No significant financial relationships to disclose.
Recollections of a New York Surgeon.
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exposures of Long Bones and Other Surgical Methods.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Doctor's Memories.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increasing bronchiectasis prevalence in Germany, 2009–2017: a population-based cohort study
Authors: Felix C. Ringshausen, Jessica Rademacher, Isabell Pink, Andrés de Roux, Lennart Hickstein, Tina Ploner, Tobias Welte, Roland Diel
Journal: European Respiratory Journal (2019)

Bronchiectasis is a chronic airway disease with often disabling symptoms, which is associated with excess mortality and a substantial economic burden for healthcare systems [1]. Although considered to be one of the most neglected diseases in respiratory medicine [2], bronchiectasis is apparently more common than previously thought [3, 4]. While trends regarding its epidemiology have been published for the UK and the USA, with marked increases in prevalence rates reported [5–7], such studies are missing for most countries including Germany. However, these basic epidemiological data are needed in order to inform healthcare authorities and policy makers regarding resource allocation and requirements planning. Thus, the objective of the present study was to provide insights into the trends of bronchiectasis prevalence in Germany. Bronchiectasis prevalence in Germany increased on average by 10% per year between 2009 and 2017 <http://bit.ly/2P4KcyW> We thank the team of Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), Annegret Zurawski, Inga Kwapniewska and Anne Hösel for their great support of bronchiectasis research within the German Center for Lung Research (DZL).
Response to: ‘Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease’ by Lai <i>et al</i>
Authors: Laurence Fardet, Irene Petersen, Irwin Nazareth
Journal: Annals of the Rheumatic Diseases (2019)

Response to: 'Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease' by Lai et alWe thank Lai et al for their correspondence 1 in which they share their study findings that endorse our own study findings 2 reporting an absence of a link between hydroxychloroquine and Alzheimer's disease.More robust research on the topic emerging from randomised trials would of course be welcomed.However, it should be kept in mind that the effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease has been investigated in 2001 in a randomised, placebo-controlled trial, and the results of the study showed no effect of treatment against placebo. 3Taken all together, these results from two large national databases and a randomised controlled trial are reassuring.Therefore, we do agree with Lai et al that withdrawal of hydroxychloroquine in people on long-term therapy, especially in older people and those receiving the drug for an autoimmune disease, is not justified.